BRIEF published on 11/04/2024 at 18:10, 16 days 16 hours ago Lepermislibre: Update of share capital and voting rights Share Capital Voting Rights Actions Update Thefreepermit
BRIEF published on 10/09/2024 at 18:10, 1 month 11 days ago LePERMISLIBRE announces a drop in turnover in Q3 2024 Future Growth Investments Turnover Olympic Games TheLIBREPERMIT
PRESS RELEASE published on 10/09/2024 at 18:05, 1 month 11 days ago Revenue for the third quarter of 2024 lePERMISLIBRE reports 29% drop in Q3 2024 revenue due to seasonal and regional factors, anticipates recovery in Q4 2024 with new partnerships for sales growth in 2025 Sales Growth LePERMISLIBRE Recovery New Partnerships Q3 2024 Revenue
BRIEF published on 10/02/2024 at 18:10, 1 month 18 days ago Lepermislibre: Monthly information on shares and voting rights Share Capital Voting Rights Actions Monthly Report Thefreepermit
BRIEF published on 09/24/2024 at 08:55, 1 month 27 days ago LePERMISLIBRE Publishes First Semester 2024 Results Financial Results Strategic Adjustments Driving School Cost Optimisation Profitability Goals
PRESS RELEASE published on 09/24/2024 at 08:50, 1 month 27 days ago lePERMISLIBRE publishes its results of the first semester of 2024 lePERMISLIBRE publishes its 2024 first semester results, showing strategic moves towards profitability amidst market challenges Profitability LePERMISLIBRE 2024 Results Driving School
BRIEF published on 09/03/2024 at 18:10, 2 months 17 days ago Lepermislibre: Information on Share Capital and Voting Rights Share Capital Voting Rights Actions AMF Thefreepermit
BRIEF published on 08/02/2024 at 18:10, 3 months 18 days ago Lepermislibre announces its share capital and voting rights Share Capital Voting Rights Actions Euronext Growth Free License
BRIEF published on 07/10/2024 at 18:10, 4 months 10 days ago Lepermislibre publishes its turnover for the first half of 2024 Financial Results Online Driving School Turnover Free License First Half Of 2024
PRESS RELEASE published on 07/10/2024 at 18:05, 4 months 10 days ago lePERMISLIBRE publishes its revenue for the first semester of 2024 lePERMISLIBRE reports a 15% decrease in sales for the first semester of 2024, driven by a 21% drop in CPF learner revenues. Strategic adjustments aim to enhance revenue sources Revenue LePERMISLIBRE Strategic Adjustments First Semester CPF Learners
Published on 11/21/2024 at 10:03, 40 minutes ago Pixotope Launches Revolutionary AI-Powered Graphics Integration Tool for Broadcast Industry
Published on 11/21/2024 at 10:00, 43 minutes ago BluSky Carbon JV Entity BluMountain Enters into JV Partnership in Southeastern USA
Published on 11/21/2024 at 09:00, 1 hour 43 minutes ago ProScore Announces Domestic Content Solution for Inflation Reduction Act Requirements
Published on 11/21/2024 at 00:35, 10 hours 8 minutes ago Vision Marine Technologies Establishes a Strategic Hub for Electric Boat Sales, Rentals, and Distribution, Marking a Milestone at Dania Pointe’s Grand Opening of Aileron Residences
Published on 11/21/2024 at 00:25, 10 hours 18 minutes ago Biomind Labs Welcomes U.S. Policy Shift as a Historic Milestone for Psychedelic Therapies
Published on 11/21/2024 at 10:30, 13 minutes ago MS Industrie AG publishes unaudited key figures for the first 3 quarters 2024
Published on 11/21/2024 at 10:04, 38 minutes ago Supervisory Board appoints Carsten Schmitt as new CFO
Published on 11/21/2024 at 10:02, 41 minutes ago Supervisory Board appoints Carsten Schmitt as new CFO
Published on 11/21/2024 at 10:00, 43 minutes ago Nabaltec AG continues solid earnings performance in third quarter of 2024
Published on 11/21/2024 at 10:00, 43 minutes ago Deutsche Beteiligungs AG: Successful final closing of DBAG ECF IV
Published on 11/21/2024 at 06:58, 3 hours 45 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 15 hours 23 minutes ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 16 hours 58 minutes ago MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 16 hours 58 minutes ago Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 2 hours ago Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo
